Immunomediated Diseases and Innovative Therapies

Overview

The Immunomediated Diseases and Innovative Therapies is a heterogeneous area composed by both translational and clinical research groups which cover fields such as immunology, respiratory and systemic diseases, pharmacology, clinical biochemistry, rheumatology, advanced therapies or transfusional medicine. Its main strength derives precisely from this heterogeneity and the complementarity of the scientific interests and expertise of the different groups, many of which are currently joining efforts and synergizing in a variety of collaborative research projects.

Publications

229

total

1430

impact factor

6.25

average impact factor

Group Leader: Rafael Parra López

team

zoom

download

Our research activity is adressed to several related fields of interest. We are interested in transfusion of blood components, in red blood cell alterations during the conservation period and in the use of extra-corporeal photoaferesis.

We work on the molecular and serological characterization of human blood groups and we are interested in non-invasive fetal genotyping strategies to look into blood group incompatibilities. We are developing iPSC lines and making red blood cells “in vitro” with modified blood group antígens.

We explore the molecular mechanisms and the genotype-phenotype correlation of congenital coagulopaties, hemorrhagic diathesis and other associated congenital pathologies. We have developed new tools based on massive sequencing techniques applied to molecular analysis, prenatal diagnosis and genetic counselling.

Another field of interest is the study of virus and other blood borne pathogens which may pose at risk the transfusion of products supplied by the Banc de Sang i Teixits.

We investigate in clinical immunology and we have developed our own HLA and KIR typing protocols. Cell therapy is a growing field and we are interested in cord blood banking and new therapeutic uses of cord blood, in obtaining and storing virus specific T lymphocytes and in developing adoptive cell therapy in hematopoietic cell transplantation and regenrative medicine.

21

total

108

impact factor

5^.16

average impact factor

SELECTED ARTICLES

Borràs N, Orriols G, Batlle J, Pérez-Rodríguez A, Fidalgo T, Martinho P, López-Fernández MF, Rodríguez-Trillo Á, Lourés E, Parra R, Altisent C, Cid AR, Bonanad S, Cabrera N, Moret A, Mingot-Castellano ME, Navarro N, Pérez-Montes R, Marcellin S, Moreto A, Herrero S, Soto I, Fernández-Mosteirín N, Jiménez-Yuste V, Alonso N, de Andrés-Jacob A, Fontanes E, Campos R, Paloma MJ, Bermejo N, Berrueco R, Mateo J, Arribalzaga K, Marco P, Palomo Á, Quismondo NC, Iñigo B, Nieto MDM, Vidal R, Martínez MP, Aguinaco R, Tenorio JM, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J, Rodríguez-González R, García-Candel F, Dobón M, Aguilar C, Vidal F, Corrales I.
Unraveling the effect of silent, intronic and missense mutations on VWF splicing: contribution of next generation sequencing in the study of mRNA.
Haematologica. 2019 Mar;104(3):587-598.
doi: 10.3324/haematol.2018.203166.
IF: 7.570
Grau-Vorster M, Rodríguez L, Del Mazo-Barbara A, Mirabel C, Blanco M, Codinach M, Gómez SG, Querol S, García-López J, Vives J.
Compliance with Good Manufacturing Practice in the Assessment of Immunomodulation Potential of Clinical Grade Multipotent Mesenchymal Stromal Cells Derived from Wharton’s Jelly.
Cells 2019 May 21;8(5).
doi: 10.3390/cells8050484
IF: 4.829
Riveiro-Barciela M, Muñoz-Couselo E, Fernandez-Sojo J, Diaz-Mejia N, Parra-López R, Buti M.
Acute Liver Failure Due to Immune-Mediated Hepatitis Successfully Managed With Plasma Exchange: New Settings Call for New Treatment Strategies?
J Hepatol 2019 Mar;70(3):564-566.
doi: 10.1016/j.jhep.2018.10.020
IF: 18.946
Rudilla F, Franco-Jarava C, Martínez-Gallo M, Garcia-Prat M, Martín-Nalda A, Rivière J, Aguiló-Cucurull A, Mongay L, Vidal F, Solanich X, Irastorza I, Santos-Pérez JL, Tercedor Sánchez J, Cuscó I, Serra C, Baz-Redón N, Fernández-Cancio M, Carreras C, Vagace JM, Garcia-Patos V, Pujol-Borrell R, Soler-Palacín P, Colobran R.
Expanding the Clinical and Genetic Spectra of Primary Immunodeficiency-Related Disorders With Clinical Exome Sequencing: Expected and Unexpected Findings.
FRONT IMMUNOL 2019 Oct 1;10:2325.
doi: 10.3389/fimmu.2019.02325
IF: 6.429
Trucco Boggione C, Nogués N, González-Santesteban C, Mufarrege N, Luján Brajovich M, Mattaloni SM, Leri M, Biondi C, Muñiz-Diaz E, Castilho L, Cotorruelo C.
Characterization of RHD locus polymorphism in D negative and D variant donors from Northwestern Argentina
Transfusion. 2019 Oct;59(10):3236-3242.
doi: 10.1111/trf.15504
IF: 3.111

View all publications

Immunomediated Diseases and Innovative Therapies

Overview

Publications

Group Leader: Rafael Parra López

Research Areas